Immune Thrombotic Microangiopathy: An Unusual Complication of Novel Anticancer Therapy
Indian Journal of Medical and Paediatric Oncology · 01.08.2026 · 47 (04) · 326-328
DOI: 10.1055/s-0046-1824554 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 01.08.2026. Verfasst von Shruti Prem Sudha und 3 weiteren Autor:innen.
Abstract (Originalsprache)
AbstractThrombotic microangiopathy (TMA) and thrombotic thrombocytopenic purpura (TTP) are rare potentially life-threatening complications in the oncology setting. The rapid approval of new drugs in oncology brings challenges since these can cause TMA/TTP by unexpected mechanisms. Additionally, confounding factors in oncology patients like sepsis and coagulopathy make recognition of TMA difficult.Trastuzumab–emtansine (TDM1) is a HER2-targeted antibody–drug conjugate. The antibody is the anti-HER2 IgG1 trastuzumab, and the cytotoxin emtansine (DM1) is a microtubule inhibitor. TTP has not been reported with TDM1 therapy previously. Here, we discuss a patient with breast cancer who developed immune-mediated TMA/acquired TTP after her therapy was switched from trastuzumab to TDM1 and was treated successfully with plasmapheresis and rituximab.
Zitieren
APA
Sudha, S. P., Yetisyigit, T., Alkaabi, L. K., & Abdulqadir, S. M. (2026). Immune Thrombotic Microangiopathy: An Unusual Complication of Novel Anticancer Therapy. Indian Journal of Medical and Paediatric Oncology, 47(04), 326-328. https://doi.org/10.1055/s-0046-1824554
Vancouver
Sudha SP, Yetisyigit T, Alkaabi LK, Abdulqadir SM. Immune Thrombotic Microangiopathy: An Unusual Complication of Novel Anticancer Therapy. Indian Journal of Medical and Paediatric Oncology. 2026;47(04):326-328. doi:10.1055/s-0046-1824554
BibTeX
@article{Sudha2026,
author = {Sudha, Shruti Prem and Yetisyigit, Tarkan and Alkaabi, Latifa Khalifa and Abdulqadir, Seemal Maqsood},
title = {Immune Thrombotic Microangiopathy: An Unusual Complication of Novel Anticancer Therapy},
journal = {Indian Journal of Medical and Paediatric Oncology},
year = {2026},
volume = {47},
number = {04},
pages = {326--328},
doi = {10.1055/s-0046-1824554}
}
EUVIMED